-
Posted by
Two Blokes Jun 28 -
Filed in
Stock
-
5 views
Arcutis Biotherapeutics' ZORYVE (roflumilast) offers superior efficacy and safety over current topical treatments for mild-to-moderate atopic dermatitis. The atopic dermatitis market is large and shifting away from steroids, positioning Arcutis to capture significant share, especially via primary care channels. Arcutis is financially strong, with over 30 months of cash runway and no anticipated need for equity dilution before reaching profitability in 2026.
